PROBLEM STATEMENT: Infection with retroviruses such as human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1) have been shown to lead to neurodegenerative diseases such as HIV-associated dementia (HAD) or neuroAIDS and HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), respectively. APPROACH: HIV-1-induced neurologic disease is associated with an influx of HIV-infected monocytic cells across the blood-brain barrier. Following neuroinvasion, HIV-1 and viral proteins, in addition to cellular mediators released from infected and uninfected cells participate in astrocytic and neuronal dysregulation, leading to mild to severe neurocognitive disorders. RESULTS: The molecular architecture of viral regulatory components including the Long Terminal Repeat (LTR), genes encoding the viral proteins Tat, Vpr and Nef as well as the envelope gene encoding gp120 and gp41 have been implicated in 'indirect' mechanisms of neuronal injury, mechanisms which are likely responsible for the majority of CNS damage induced by HIV-1 infection. The neuropathogenesis of HAM/TSP is linked, in part, with both intra-and extracellular effectors functions of the viral transactivator protein Tax and likely other viral proteins. Tax is traditionally known to localize in the nucleus of infected cells serving as a regulator of both viral and cellular gene expression. CONCLUSION/RECOMMENDATIONS: However, recent evidence has suggested that Tax may also accumulate in the cytoplasm and be released from the infected cell through regulated cellular secretion processes. Once in the extracellular environment, Tax may cause functional alterations in cells of the peripheral blood, lymphoid organs and the central nervous system. These extracellular biological activities of Tax are likely very relevant to the neuropathogenesis of HTLV-1 and represent attractive targets for therapeutic intervention.
PROBLEM STATEMENT: Infection with retroviruses such as human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1) have been shown to lead to neurodegenerative diseases such as HIV-associated dementia (HAD) or neuroAIDS and HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), respectively. APPROACH: HIV-1-induced neurologic disease is associated with an influx of HIV-infected monocytic cells across the blood-brain barrier. Following neuroinvasion, HIV-1 and viral proteins, in addition to cellular mediators released from infected and uninfected cells participate in astrocytic and neuronal dysregulation, leading to mild to severe neurocognitive disorders. RESULTS: The molecular architecture of viral regulatory components including the Long Terminal Repeat (LTR), genes encoding the viral proteins Tat, Vpr and Nef as well as the envelope gene encoding gp120 and gp41 have been implicated in 'indirect' mechanisms of neuronal injury, mechanisms which are likely responsible for the majority of CNS damage induced by HIV-1 infection. The neuropathogenesis of HAM/TSP is linked, in part, with both intra-and extracellular effectors functions of the viral transactivator protein Tax and likely other viral proteins. Tax is traditionally known to localize in the nucleus of infected cells serving as a regulator of both viral and cellular gene expression. CONCLUSION/RECOMMENDATIONS: However, recent evidence has suggested that Tax may also accumulate in the cytoplasm and be released from the infected cell through regulated cellular secretion processes. Once in the extracellular environment, Tax may cause functional alterations in cells of the peripheral blood, lymphoid organs and the central nervous system. These extracellular biological activities of Tax are likely very relevant to the neuropathogenesis of HTLV-1 and represent attractive targets for therapeutic intervention.
Authors: R S Klein; K C Williams; X Alvarez-Hernandez; S Westmoreland; T Force; A A Lackner; A D Luster Journal: J Immunol Date: 1999-08-01 Impact factor: 5.422
Authors: Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke Journal: ACS Chem Neurosci Date: 2015-06-19 Impact factor: 4.418
Authors: Hangxiu Xu; Mihyun Bae; Luis B Tovar-y-Romo; Neha Patel; Veera Venkata Ratnam Bandaru; Daniel Pomerantz; Joseph P Steiner; Norman J Haughey Journal: J Neurosci Date: 2011-11-23 Impact factor: 6.167
Authors: Hyo Young Jung; Hyun Jung Kwon; Woosuk Kim; Sung Min Nam; Jong Whi Kim; Kyu Ri Hahn; Dae Young Yoo; Moo-Ho Won; Yeo Sung Yoon; Dae Won Kim; In Koo Hwang Journal: Neurochem Res Date: 2018-11-20 Impact factor: 3.996
Authors: Fernando Medina; Sebastian Quintremil; Carolina Alberti; Andres Barriga; Luis Cartier; Javier Puente; Eugenio Ramírez; Arturo Ferreira; Yuetsu Tanaka; Maria Antonieta Valenzuela Journal: AIDS Res Hum Retroviruses Date: 2014-01-24 Impact factor: 2.205
Authors: Paula Desplats; Wilmar Dumaop; David Smith; Anthony Adame; Ian Everall; Scott Letendre; Ronald Ellis; Mariana Cherner; Igor Grant; Eliezer Masliah Journal: Neurology Date: 2013-03-13 Impact factor: 9.910